A Phase 3 interventional study of Pancreatic enzyme capsules and Placebo in Acute Necrotizing Pancreatitis and Pancreatic Exocrine Insufficiency, sponsored by Asian Institute of Gastroenterology, India. Recruiting at 4 sites in India. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Asian Institute of Gastroenterology, India · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this multicenter, double blinded, placebo-controlled, 1:1 parallel group RCT, the investigators propose to evaluate the impact of pancreatic exocrine replacement therapy on patients with acute necrotizing pancreatitis (ANP). The investigators will include patients of 18-60yrs age and both genders with >50% pancreatic parenchymal necrosis and at least 5% loss of body weight.
The primary outcome measure is percent change in body weight at 3 months after enrolment. The intervention will include pancreatic enzyme consisting of 25000 IU of lipase and similar appearing placebo.
Acute pancreatitis (AP), an inflammatory disorder of the pancreas, is mild and self-limiting in most patients. Around 10-20% of AP patients develop acute necrotizing pancreatitis (ANP) which is characterized by destruction of both pancreatic and peripancreatic tissue and is associated with high rate of morbidity and mortality due to both local and systemic complications.
Early recognition and close monitoring of affected patients is crucial. Treatment consists of goal-directed intravenous fluid resuscitation, pain control, and enteral nutrition as early as possible. While sterile necrosis might resolve with above conservative measures, infected necrosis requires antibiotics and further interventions such as percutaneous drainage, minimally invasive surgeries, and endoscopic necrosectomy.
In ANP patients there is direct destruction of acinar tissue that results in pancreatic exocrine insufficiency (PEI). In PEI there is insufficient secretion of pancreatic enzymes that causes inadequate nutrient digestion and absorption resulting in weight loss, malnutrition, metabolic bone disease and fat-soluble vitamins and mineral deficiencies. The risk of PEI after ANP is about 25% over 3 years. According to two meta-analysis, PEI was found to be more prevalent during the index AP episode and it remained persistent in about half of the study population at follow-ups. They also reported that the risk of developing PEI is more in those with alcoholic etiology and severe and necrotizing pancreatitis. Hence, management of PEI following ANP is important to improve nutritional status and quality of life. Pancreatic enzyme replacement therapy (PERT) is the mainstay of treatment for PEI. While the use of PERT is well-established in chronic pancreatitis, its efficacy in patients with ANP is still unclear. Hence, in this study, the investigators aim to provide insights into the potential benefits of enzyme supplementation in patients with ANP by evaluating nutritional status, clinical outcomes, and quality of life.
This is a multicenter, double blinded, placebo-controlled, 1:1 parallel group RCT, the investigators propose to evaluate the impact of pancreatic exocrine replacement therapy on patients with acute necrotizing pancreatitis (ANP). The investigators will include patients of 18-60yrs age and both genders with >50% pancreatic parenchymal necrosis and at least 5% loss of body weight.
The primary outcome measure is percent change in body weight at 3 months after enrolment. The intervention will include pancreatic enzyme consisting of 25000 IU of lipase and similar appearing placebo.
75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.
This study's planned enrollment of 140 is above the median of 70 across 47 interventional studies indexed under Pancreatitis, Acute Necrotizing.
Browse Pancreatitis, Acute Necrotizing studies →Asian Institute of Gastroenterology, India is the lead sponsor of 135 studies on the registry; 59 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pancreatic enzyme capsules
Drug: Placebo Similar appearing glucose capsules
Drug: Placebo
Enteric coated pancreatic enzyme
Similar appearing glucose capsules
Percent change in body weight
Body weight (in kg) will be measured at baseline and again at 3 months follow-up, and the difference between the two time points will be used to assess the effect of the intervention on patients' weight status. The change will be expressed as percent change of weight 3 months compared to baseline weight.
Time frame: 3 months
Change in quality of life
Quality of life will be assessed by the Short Form (SF)-36 tool. This is a standardised and validated questionnaire based scoring tool that contains 36 questions dealing with 8 domains of quality of life. The lowest score in this tool is 0 and the highest score is 100, a higher score indicating better quality of life.
Time frame: 3 months
Change in pancreatic exocrine function
Exocrine function will be assessed by the Fecal elastase test and will be expressed as microgram of elastase per gram of stool. Higher value indicates better exocrine function. The cut-off value that will be used is 200mcg/gm elastase, below which exocrine insufficiency will be considered to be present.
Time frame: 3 months
Change in nutritional status: Subjective Global Assesment (SGA)
This is a semiquantitative questionnaire based nutritional assessment tool which classifies the nutritional status as SGA A (normal nutrition), SGA B (mild/moderate malnutrition) and SGC C (severe malnutrition)
Time frame: 3 months
Change in nuritional status: Anthropometry
Skin fold thickness (in mm) over the triceps muscle at the mid arm level.
Time frame: 3 months
Change in nutritional change: Anthropometry
Mid-arm circumference (MAC) in cm.
Time frame: 3 months
Change in nutritional status: Anthropometry
Mid-upper arm muscle circumference (MAMC) in cm.
Time frame: 3 months
Change in nutritional status: Anthropomentry
Mid-arm muscle area (MAMA) in cm square.
Time frame: 3 months
Change in nutritional status: Biochemical assessment
Hemoglobin in gm/dL
Time frame: 3 months
Change in nutritional status: Biochemical assessment
Serum prealbumin in mg/dL
Time frame: 3 months
Change in nutritional status: Biochemical assessment
Vitamin D
Time frame: 3 months
Change in nutritional status: Biochemical assessment
Vitamin B12
Time frame: 3 months
Change in the endocrine status
Fasting blood glucose (FBS)
Time frame: 3 months
Change in the endocrine status
HbA1c
Time frame: 3 months
Change in the endocrine status
Stimulated C-peptide
Time frame: 3 months
Change in patient's impression of change after treatment
This will be evaluated using the Patient's Global Impression of Change (PGIC). The score ranges from 1-7, with a score of 1 indicating very much improved and 7 indicating very much worse
Time frame: 3 months
Readmission after onset of treatment
Readmission to hospital
Time frame: 3 months
Change in body composition (Bioimpedence analysis): Body fat mass (kg)
Total body fat will be assessed using Bioimpedence analysis (BIA) This is a non-invasive method that operates by sending a low-level, imperceptible electrical current through the body. The normal range is 10-20kg.
Time frame: 3 months
Change in body composition (Bioimpedence analysis): Skeletal muscle mass (kg)
Skeletal muscle mass will be assessed using Bioimpedence analysis (BIA) This is a non-invasive method that operates by sending a low-level, imperceptible electrical current through the body.
Time frame: 3 months
Change in body composition (Bioimpedence analysis): Total body water (litres)
Total body water will be quantified using Bioimpedence analysis (BIA) This is a non-invasive method that operates by sending a low-level, imperceptible electrical current through the body.
Time frame: 3 months
Change in body composition (Bioimpedence analysis): Phase angle at 50kH (degrees)
Cell membrane integrity will be assessed using the phase angle function of Bioimpedence analysis (BIA) This is a non-invasive method that operates by sending a low-level, imperceptible electrical current through the body.
Time frame: 3 months
Change in body composition (Bioimpedence analysis): Visceral fat level (numerical unit; normal range (1-12).
Visceral fat level will be assessed using Bioimpedence analysis (BIA) This is a non-invasive method that operates by sending a low-level, imperceptible electrical current through the body. The normal range is from 1-12, a loser value indicating lower visceral fat and higher value indicates larger visceral fat.
Time frame: 3 months
Plan to share: Undecided
Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pancreatic Enzyme
Pancreatitis, Acute Necrotizing →
Asian Institute of Gastroenterology, India →